Table 1.
Characteristic | Everolimus 70 mg/week (N = 99) | Everolimus 10 mg/day (N = 100) |
---|---|---|
Age, median y (range) | 61.0 (32–81) | 61.5 (25–84) |
Sex, N (%) | ||
Male | 52 (52.5) | 52 (52.0) |
Female | 47 (47.5) | 48 (48.0) |
WHO PS, N (%) | ||
0 | 45 (45.5) | 50 (50.0) |
1 | 52 (52.5) | 44 (44.0) |
2 | 2 (2.0) | 5 (5.0) |
≥1 | 54 (54.5) | 49 (49.0) |
Missing | 0 | 1 (1.0) |
Primary site of cancer, N (%) | ||
Colon | 72 (72.7) | 76 (76.0) |
Rectum | 21 (21.2) | 14 (14.0) |
Other a | 6 (6.1) | 10 (10.0) |
Histology/cytology, N (%) | ||
Adenocarcinoma | 93 (93.9) | 95 (95.0) |
Mucinous adenocarcinoma | 6(6.1) | 4 (4.0) |
Other | 0 | 1 (1.0) |
Histologic grade, N (%) | ||
Well differentiated | 9 (9.1) | 13 (13.0) |
Moderately differentiated | 78 (78.8) | 64 (64.0) |
Poorly differentiated | 11 (11.1) | 17 (17.0) |
Unknown | 1 (1.0) | 6 (6.0) |
Time since initial diagnosis, N (%) | ||
≤12 months | 2 (2.0) | 3 (3.0) |
>12 months to ≤ 24 months | 23 (23.2) | 23 (23.0) |
>24 months | 74 (74.7) | 74 (74.0) |
Number of organs involved, N (%) | ||
≤2 | 47 (47.5) | 52 (52.0) |
>2 | 52 (52.5) | 48 (48.0) |
Visceral involvement, N (%) | 97 (98.0) | 100 (100) |
PIK3CA, N (%) | ||
Wild-type | 76 (76.8) | 76 (76.0) |
Mutation | 3 (3.0) | 5 (5.0) |
Missing | 20 (20.2) | 19 (19.0) |
PTEN expression, N (%) | ||
Low | 43 (43.4) | 26 (26.0) |
Normal | 30 (30.3) | 46 (46.0) |
Missing | 26 (26.3) | 28 (28.0) |
KRAS, N (%) | ||
Wild type | 46 (46.5) | 40 (40.0) |
Mutation | 33 (33.3) | 41 (41.0) |
Missing | 20 (20.2) | 19 (19.0) |
BRAF, N (%) | ||
Wild type | 71 (71.2) | 72 (72.0) |
Mutation | 8 (8.1) | 7 (7.0) |
Missing | 20 (20.2) | 21 (21.0) |
Includes cecum (N = 5), colon and rectum (N = 3), rectosigmoid (N = 4), sigmoid colon (N = 2), colorectal (N = 1), and splenic-colon corner (N = 1).
PIK3CA, phosphatidylinositol 3-kinase catalytic subunit; PTEN, phosphatase and tensin homolog; WHO PS, World Health Organization performance status.